Transient MOG antibody seroconversion associated with immunomodulating therapy
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
2020
|
| In: |
Multiple Sclerosis and Related Disorders
Year: 2019, Jahrgang: 37 |
| ISSN: | 2211-0356 |
| DOI: | 10.1016/j.msard.2019.101420 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.msard.2019.101420
|
| Verfasserangaben: | Marc Pawlitzki, Christin Campe, Leoni Rolfes, Hans-Jochen Heinze, Frank Leypoldt, Klaus-Peter Wandinger, Markus Reindl, Brigitte Wildemann, Sven Jarius, Peter Körtvelyessy |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1694034496 | ||
| 003 | DE-627 | ||
| 005 | 20230427100354.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200403r20202019xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.msard.2019.101420 |2 doi | |
| 035 | |a (DE-627)1694034496 | ||
| 035 | |a (DE-599)KXP1694034496 | ||
| 035 | |a (OCoLC)1341313665 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Pawlitzki, Marc |e VerfasserIn |0 (DE-588)1155421779 |0 (DE-627)1017709602 |0 (DE-576)501630686 |4 aut | |
| 245 | 1 | 0 | |a Transient MOG antibody seroconversion associated with immunomodulating therapy |c Marc Pawlitzki, Christin Campe, Leoni Rolfes, Hans-Jochen Heinze, Frank Leypoldt, Klaus-Peter Wandinger, Markus Reindl, Brigitte Wildemann, Sven Jarius, Peter Körtvelyessy |
| 264 | 1 | |c 2020 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 04.05.2020 | ||
| 500 | |a Available online: 28 September 2019 | ||
| 500 | |a Immunoglobulin G (IgG) autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) have recently been associated with autoimmune CNS demyelination. We present the case of a 35-year-old patient who was seronegative for MOG-IgG (as confirmed by means of three independent immunoassays) during two corticosteroid-responsive attacks of brainstem encephalitis and optic neuritis, respectively, but turned positive for MOG-IgG under treatment with interferon-beta (IFN-beta), which was commenced 6 months after onset of the first attack. MOG-IgG serum levels declined after therapy was switched to glatiramer acetate. The fact that seroconversion was first observed under treatment with IFN-beta is in accordance with previous evidence suggesting a role of IFN-beta in disease exacerbation in antibody-mediated disorders | ||
| 534 | |c 2019 | ||
| 700 | 1 | |a Campe, Christin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rolfes, Leoni |e VerfasserIn |4 aut | |
| 700 | 1 | |a Heinze, Hans-Jochen |d 1953- |e VerfasserIn |0 (DE-588)172154189 |0 (DE-627)69706915X |0 (DE-576)133025691 |4 aut | |
| 700 | 1 | |a Leypoldt, Frank |d 1976- |e VerfasserIn |0 (DE-588)129347795 |0 (DE-627)394260317 |0 (DE-576)297612670 |4 aut | |
| 700 | 1 | |a Wandinger, Klaus-Peter |d 1966- |e VerfasserIn |0 (DE-588)129121215 |0 (DE-627)389669210 |0 (DE-576)297504142 |4 aut | |
| 700 | 1 | |a Reindl, Markus |e VerfasserIn |0 (DE-588)1158607156 |0 (DE-627)1020597453 |0 (DE-576)504248413 |4 aut | |
| 700 | 1 | |a Wildemann, Brigitte |e VerfasserIn |0 (DE-588)110203844 |0 (DE-627)510150004 |0 (DE-576)171831330 |4 aut | |
| 700 | 1 | |a Jarius, Sven |e VerfasserIn |0 (DE-588)1054615918 |0 (DE-627)791654818 |0 (DE-576)410367478 |4 aut | |
| 700 | 1 | |a Körtvélyessy, Péter |d 1977- |e VerfasserIn |0 (DE-588)1042157146 |0 (DE-627)768240603 |0 (DE-576)393716511 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Multiple Sclerosis and Related Disorders |d Amsterdam [u.a.] : Elsevier, 2012 |g 37(2020) Artikel-Nummer 101420, 3 Seiten |h Online-Ressource |w (DE-627)683365622 |w (DE-600)2645330-7 |w (DE-576)357960025 |x 2211-0356 |7 nnas |a Transient MOG antibody seroconversion associated with immunomodulating therapy |
| 773 | 1 | 8 | |g volume:37 |g year:2020 |g extent:3 |a Transient MOG antibody seroconversion associated with immunomodulating therapy |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.msard.2019.101420 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200504 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 1054615918 |a Jarius, Sven |m 1054615918:Jarius, Sven |d 910000 |d 911100 |e 910000PJ1054615918 |e 911100PJ1054615918 |k 0/910000/ |k 1/910000/911100/ |p 9 | ||
| 998 | |g 110203844 |a Wildemann, Brigitte |m 110203844:Wildemann, Brigitte |d 910000 |d 911100 |e 910000PW110203844 |e 911100PW110203844 |k 0/910000/ |k 1/910000/911100/ |p 8 | ||
| 999 | |a KXP-PPN1694034496 |e 3656754969 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title":"Transient MOG antibody seroconversion associated with immunomodulating therapy","title_sort":"Transient MOG antibody seroconversion associated with immunomodulating therapy"}],"type":{"media":"Online-Ressource","bibl":"article-journal"},"person":[{"role":"aut","given":"Marc","roleDisplay":"VerfasserIn","display":"Pawlitzki, Marc","family":"Pawlitzki"},{"display":"Campe, Christin","roleDisplay":"VerfasserIn","given":"Christin","family":"Campe","role":"aut"},{"role":"aut","family":"Rolfes","roleDisplay":"VerfasserIn","given":"Leoni","display":"Rolfes, Leoni"},{"role":"aut","given":"Hans-Jochen","roleDisplay":"VerfasserIn","display":"Heinze, Hans-Jochen","family":"Heinze"},{"family":"Leypoldt","given":"Frank","roleDisplay":"VerfasserIn","display":"Leypoldt, Frank","role":"aut"},{"role":"aut","display":"Wandinger, Klaus-Peter","roleDisplay":"VerfasserIn","given":"Klaus-Peter","family":"Wandinger"},{"role":"aut","family":"Reindl","display":"Reindl, Markus","roleDisplay":"VerfasserIn","given":"Markus"},{"role":"aut","family":"Wildemann","roleDisplay":"VerfasserIn","display":"Wildemann, Brigitte","given":"Brigitte"},{"display":"Jarius, Sven","roleDisplay":"VerfasserIn","given":"Sven","family":"Jarius","role":"aut"},{"family":"Körtvélyessy","display":"Körtvélyessy, Péter","roleDisplay":"VerfasserIn","given":"Péter","role":"aut"}],"name":{"displayForm":["Marc Pawlitzki, Christin Campe, Leoni Rolfes, Hans-Jochen Heinze, Frank Leypoldt, Klaus-Peter Wandinger, Markus Reindl, Brigitte Wildemann, Sven Jarius, Peter Körtvelyessy"]},"id":{"eki":["1694034496"],"doi":["10.1016/j.msard.2019.101420"]},"recId":"1694034496","language":["eng"],"note":["Gesehen am 04.05.2020","Available online: 28 September 2019","Immunoglobulin G (IgG) autoantibodies targeting myelin oligodendrocyte glycoprotein (MOG) have recently been associated with autoimmune CNS demyelination. We present the case of a 35-year-old patient who was seronegative for MOG-IgG (as confirmed by means of three independent immunoassays) during two corticosteroid-responsive attacks of brainstem encephalitis and optic neuritis, respectively, but turned positive for MOG-IgG under treatment with interferon-beta (IFN-beta), which was commenced 6 months after onset of the first attack. MOG-IgG serum levels declined after therapy was switched to glatiramer acetate. The fact that seroconversion was first observed under treatment with IFN-beta is in accordance with previous evidence suggesting a role of IFN-beta in disease exacerbation in antibody-mediated disorders"],"relHost":[{"title":[{"title":"Multiple Sclerosis and Related Disorders","title_sort":"Multiple Sclerosis and Related Disorders"}],"language":["eng"],"disp":"Transient MOG antibody seroconversion associated with immunomodulating therapyMultiple Sclerosis and Related Disorders","part":{"text":"37(2020) Artikel-Nummer 101420, 3 Seiten","extent":"3","volume":"37","year":"2020"},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 22.05.23"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["1.2012 -"],"origin":[{"dateIssuedDisp":"2012-","publisherPlace":"Amsterdam [u.a.]","publisher":"Elsevier","dateIssuedKey":"2012"}],"recId":"683365622","id":{"zdb":["2645330-7"],"eki":["683365622"],"issn":["2211-0356"]}}],"physDesc":[{"extent":"3 S."}],"origin":[{"dateIssuedDisp":"2020","dateIssuedKey":"2020"}]} | ||
| SRT | |a PAWLITZKIMTRANSIENTM2020 | ||